J&J taps peptide technology in $1.15B discovery deal
- Janssen Pharmaceuticals, part of Johnson & Johnson, has hooked rights to PeptiDream's Peptide Discovery Platform System (PDPS) in a discovery deal to find peptide hits for metabolic and cardiovascular disease.
- In a deal valued at $1.15 billion, PeptiDream will find macrocyclic/constrained peptide hits and create peptide and small molecule therapeutics.
- In return for pre-clinical, clinical and commercialization milestone payments, Janssen has development and commercialization rights to all compounds, as well as an exercisable option to peptide-drug conjugate (PDC) use and applications. PeptiDream will get undisclosed levels of royalties.
One of Janssen Pharmaceuticals' areas of therapeutic focus is cardiovascular and metabolism, and this deal will serve to boost the company's early-stage pipeline, in both biologics and small molecule drugs.
Janssen is just the most recent in a string of deals for PeptiDream, which was founded in 2006. The company has ongoing discovery deals with 16 of the leading pharmaceutical companies, including Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline and Novartis. PeptiDream has also licensed its discovery platform to Bristol-Myers-Squibb, Novartis, Lilly and Roche's Genentech.
"Over the past few years PeptiDream has greatly expanded our ability to turn PDPS-identified peptide candidates into peptide therapeutics, small molecule drugs and peptide drug conjugates [PDCs], and we greatly look forward to working with a world-renowned organization like Janssen to leverage these capabilities to discover and development the next generation of first-in-class and best-in-class therapeutics," said Kiichi Kubota, CEO and president of PeptiDream.
Just last month, PeptiDream announced the fifth milestone from its macrocyclic peptide drug discovery deal with Bristol-Myers Squibb, when it identified a lead compound, and the first milestone in the macrocyclic peptide drug discovery alliance with Shionogi, based on the identification of a set of candidates.
- PeptiDream Press release
Follow Suzanne Elvidge on Twitter